Asian Promise For Ocata’s Macular Degeneration Cell Therapy
This article was originally published in PharmAsia News
Executive Summary
U.S. regenerative ophthalmology venture Ocata Therapeutics has disclosed new positive top-line results from the first ever clinical trial in Asian patients with a stem cell-derived cell therapy.